Condition
Recurrent Prostate Carcinoma
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 63 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
60 shownMetabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT TrialNCT07202247 · 2025-11-05
RECRUITINGREVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac TrialNCT06650579 · 2025-01-31
RECRUITING99mTc-PSMA-I&S Biodistribution in Patients With Prostate CancerNCT04857502 · 2021-04-27
RECRUITINGCollecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial CancerNCT01050504 · 2009-08-01
RECRUITINGComparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate CancerNCT05779943 · 2023-04-27
ACTIVE_NOT_RECRUITINGSMMART Adaptive Clinical Treatment (ACT) TrialNCT05238831 · 2023-01-30
WITHDRAWNTime-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal CancersNCT05722288 · 2023-01-20
ACTIVE_NOT_RECRUITINGGallium-68 PSMA-11 PET in Participants With Prostate CancerNCT05034562 · 2022-09-26
WITHDRAWNTesting the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVNCT04514484 · 2021-11-22
ACTIVE_NOT_RECRUITINGWhite Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CANCT04519879 · 2021-05-10
SUSPENDEDMeasuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair VariationsNCT04550494 · 2021-04-26
ACTIVE_NOT_RECRUITINGAntiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate CancerNCT03902951 · 2021-03-17
ACTIVE_NOT_RECRUITINGGallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate CancerNCT03698370 · 2020-12-15
COMPLETEDProspective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology ValidationNCT04457232 · 2020-09-09
ACTIVE_NOT_RECRUITINGA Study To Evaluate Hypofractionated Proton Therapy Or IMRT For Recurrent, Oligometastatic Prostate CancerNCT04190446 · 2020-01-06
ACTIVE_NOT_RECRUITINGSalvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate CancerNCT03796767 · 2019-09-09
COMPLETEDGallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After SurgeryNCT03515577 · 2019-04-12
COMPLETEDMulticenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical ProstatectomyNCT03582774 · 2018-07-12
ACTIVE_NOT_RECRUITINGRadiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE TrialNCT03371719 · 2018-06-20
ACTIVE_NOT_RECRUITINGTrametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate CancerNCT02881242 · 2018-01-30
ACTIVE_NOT_RECRUITING68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial TreatmentNCT02673151 · 2017-05-20
COMPLETEDCognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate CancerNCT03016741 · 2017-03-31
ACTIVE_NOT_RECRUITINGHyperthermia and High Dose Rate Radiation Therapy in Treating Patients With Recurrent Prostate Cancer After RadiationNCT02899221 · 2017-03-21
COMPLETEDCollection of Serum Samples in Studying Emotional Stress in Patients With Prostate CancerNCT03122743 · 2017-02-22
COMPLETEDEnzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate CancerNCT02935205 · 2017-01-17
UNKNOWNEnzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate CancerNCT03123978 · 2017-01-09
COMPLETEDDocetaxel and Carboplatin for Patients With mCRPC and DNA-Repair DeficienciesNCT02985021 · 2016-11-01
TERMINATEDAbiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate CancerNCT02807805 · 2016-10-01
ACTIVE_NOT_RECRUITINGGallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial TherapyNCT02940262 · 2016-09-15
COMPLETEDBiomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7NCT02601014 · 2016-03-15
COMPLETEDNanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR MutationsNCT02646319 · 2016-01-01
COMPLETEDNiclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate CancerNCT02532114 · 2015-12-31
COMPLETEDTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)NCT02465060 · 2015-08-17
ACTIVE_NOT_RECRUITINGEnzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate CancerNCT02522715 · 2015-08-13
ACTIVE_NOT_RECRUITINGVaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate CancerNCT02499835 · 2015-07-01
COMPLETEDMetformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation TherapyNCT02420652 · 2015-06-23
TERMINATED68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate CancerNCT02488070 · 2015-06-01
COMPLETEDSipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate CancerNCT02159950 · 2015-01-01
COMPLETEDPembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With EnzalutamideNCT02312557 · 2014-11-18
ACTIVE_NOT_RECRUITINGStereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate CancerNCT02206334 · 2014-08-01
COMPLETEDGenetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide TherapyNCT02099864 · 2014-02-05
COMPLETEDItraconazole in Treating Patients With Biochemically Relapsed Prostate CancerNCT01787331 · 2013-10-29
COMPLETEDRadiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-TNCT01833208 · 2013-07-03
COMPLETEDGene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition TherapyNCT01953640 · 2013-05-30
COMPLETEDMolecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving EnzalutamideNCT02228265 · 2013-03-12
COMPLETEDFinite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate CancerNCT01786265 · 2013-02-05
ACTIVE_NOT_RECRUITINGAbiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate CancerNCT01503229 · 2012-12-01
COMPLETEDRomidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver DysfunctionNCT01638533 · 2012-08-03
COMPLETEDAbiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate CancerNCT01576172 · 2012-03-30
COMPLETEDVaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid TumorsNCT01522820 · 2012-03-01
COMPLETEDTivantinib in Treating Patients With Metastatic Prostate CancerNCT01519414 · 2012-01-11
COMPLETEDBicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate CancerNCT01251861 · 2011-03-17
COMPLETEDBicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate CancerNCT01120236 · 2010-12-01
COMPLETEDDocetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate CancerNCT01145508 · 2010-08-01
TERMINATEDPhenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With DocetaxelNCT01253642 · 2010-07-12
TERMINATEDCixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate CancerNCT01026623 · 2009-10-01
COMPLETEDFluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone MetastasesNCT00936975 · 2009-09-01
COMPLETEDPazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone TherapyNCT00486642 · 2007-09-01
COMPLETEDCalcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate CancerNCT00536991 · 2006-10-01
TERMINATEDA Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate CancerNCT00108732 · 2006-02-01
COMPLETEDCommon interventions
Laboratory Biomarker AnalysisOTHER29Computed TomographyPROCEDURE13Pharmacological StudyOTHER11Biospecimen CollectionPROCEDURE9EnzalutamideDRUG9Positron Emission TomographyPROCEDURE8PrednisoneDRUG8Quality-of-Life AssessmentOTHER8Abiraterone AcetateDRUG7BicalutamideDRUG7Questionnaire AdministrationOTHER7Magnetic Resonance ImagingPROCEDURE6Goserelin AcetateDRUG4Leuprolide AcetateDRUG4Cytology Specimen Collection ProcedureOTHER3DocetaxelDRUG3NiclosamideDRUG3NivolumabBIOLOGICAL3Radiation TherapyRADIATION3ApalutamideDRUG2Biopsy ProcedurePROCEDURE2CarboplatinDRUG2CixutumumabBIOLOGICAL2Clinical ObservationOTHER2FlutamideDRUG2
Leading sponsors
National Cancer Institute (NCI)
14
Jonsson Comprehensive Cancer Center
7
OHSU Knight Cancer Institute
6
Mayo Clinic
4
Roswell Park Cancer Institute
4
Andrei Iagaru
3
City of Hope Medical Center
3
University of Washington
3
Emory University
2
M.D. Anderson Cancer Center
2
Mamta Parikh
2
NRG Oncology
2
Northwestern University
1
Rutgers, The State University of New Jersey
1
Seattle Institute for Biomedical and Clinical Research
1
Trial status mix
COMPLETED33
ACTIVE_NOT_RECRUITING16
TERMINATED5
RECRUITING4
WITHDRAWN2
NO_LONGER_AVAILABLE1
SUSPENDED1
UNKNOWN1
Phase mix
PHASE241
PHASE114
PHASE34
EARLY_PHASE13
NA2
PHASE41
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.